ArticleExperimental and therapeutic medicine2026
Cold agglutination as a pivotal diagnostic clue for Waldenström macroglobulinemia: A rare case report with diagnostic and therapeutic insights.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoproliferative disorder characterized by bone marrow infiltration and monoclonal immunoglobulin M (IgM) secretion, which poses diagnostic challenges in the early stage. The present study reported on a 63-year-old male with WM presenting with cough, hyperviscosity syndrome (dizziness, weakness, fatigue, blurred vision), severe anemia and cold agglutination in August 2023. After 37˚C incubation to eliminate cold agglutination interference, laboratory tests confirmed severe anemia (hemoglobin, 54 g/l), hyperglobulinemia (globulin, 92 g/l) and markedly elevated serum IgM (83.6 g/l). Peripheral blood smear showed erythrocyte rouleaux formation and plasmacytoid lymphocytes. Bone marrow biopsy revealed 80% infiltration of B-lymphomatous cells, 10% abnormal plasma cells and only 10% residual normal hematopoietic cells. Serum/urine immunoelectrophoresis identified IgM-λ paraprotein and free λ light chains. Bone marrow flow cytometry detected a prominent abnormally mature B-lymphocyte population (72.2% of lymphocytes) positive for CD19, CD20 and cytoplasmic λ (cλ); partially positive for CD23, CD25 and CD27; and negative for CD5, CD10 and CD103. Abnormal plasma cells (0.3% of nucleated cells) showed cλ restriction; strong expression of CD38, CD138 and CD19; partial expression of CD20 and CD27; and absence of CD5, CD10 and CD56. Genetic testing confirmed the MYD88 innate immune signal transduction adaptor (MYD88) L265P mutation positivity via allele-specific PCR and 14q32/11q13 translocation negativity using fluorescence
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.